ABOS vs PRTA
ABOS: Acumen Pharmaceuticals is developing a precision immunotherapy targeting toxic amyloid-beta oligomers to provide a disease-modifying treatment for Alzheimer’s disease. PRTA: Prothena is a clinical-stage biotechnology company developing novel therapies for protein dysregulation diseases like Alzheimer's and Parkinson's through a collaborative, partner-focused model.
Side-by-side fundamentals
| Metric | ABOS | PRTA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $2.10 | $8.61 | |
| Market cap | $152M | $442M | |
| Net margin FY2025, SEC XBRL | n/a | -2520.6% | |
| Operating margin FY2025, SEC XBRL | n/a | -2216.4% | |
| ROE FY2025, SEC XBRL | -172.3% | -87.0% | PRTA higher |
| ROA FY2025, SEC XBRL | -98.8% | -74.7% | PRTA higher |
| Debt / equity as of 2026-09-03 | 0.35 | 0.00 | PRTA lower |
| Revenue CAGR (3y) SEC XBRL | n/a | -43.6% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.38 | 0.77 | |
| 1-year return as of 2026-10-08 close | +11.7% | -16.8% | ABOS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.